Avantor partners with p-Chip to develop smart lab consumables

RADNOR, Pa. - Avantor, Inc. (NYSE:AVTR), a $10.34 billion market cap company with annual revenues of $6.67 billion, announced today a collaboration agreement with p-Chip Corporation to develop "Smart Consumables" by embedding microtransponder technology into laboratory and clinical supplies. According to InvestingPro analysis, Avantor maintains a "Good" Financial Health score, positioning it well for strategic initiatives.

The partnership aims to create consumables with digital tracking capabilities to ensure secure chain-of-identity and traceability in pharmaceutical and clinical workflows. The technology involves embedding p-Chip’s microtransponders—silicon chips approximately the size of a salt grain—into items like vials, slides, cassettes, tubes, and plates. For investors tracking Avantor’s growth potential, InvestingPro subscribers can access additional insights, including multiple ProTips and comprehensive financial metrics in the Pro Research Report.

These enhanced products will provide unique digital identifiers to enable end-to-end traceability and automated process control, according to the companies. The collaboration targets applications in life sciences, diagnostics, bio-manufacturing, and healthcare sectors.

"This innovation supports Avantor’s mission to enable scientific breakthroughs and allows us to meet high-value customer needs in rapidly evolving areas like personalized medicine," said Corey Walker, President of Laboratory Solutions at Avantor.

The companies stated that the technology addresses growing demands in precision and individualized therapies, where patient samples must be securely identified and monitored throughout the therapeutic process from collection to administration.

Michael Hadjisavas, Chief Operating Officer of Life Sciences and Healthcare at p-Chip Corporation, noted that the technology will help "maintain an unbroken chain-of-identity for samples and reagents."

Avantor provides products and services to customers in life sciences and advanced technology industries across 180 countries. The p-Chip technology creates "digital twins" for physical items to enhance traceability and security.

The announcement was made in a press release statement issued by the companies. Investors should note that Avantor is scheduled to report its next earnings on October 29, 2025. InvestingPro subscribers can access detailed analysis and Fair Value estimates, along with exclusive insights available in the comprehensive Pro Research Report, one of 1,400+ deep-dive analyses available on the platform.

In other recent news, Avantor Inc. reported its second-quarter earnings for 2025, with revenue remaining stable year-over-year at $1.68 billion. Although there was a slight decline in adjusted earnings per share, the company’s strategic initiatives have garnered positive investor sentiment. Additionally, Avantor announced a strategic partnership with BlueWhale Bio to enhance CAR-T cell therapy manufacturing. This collaboration aims to leverage Avantor’s bioprocessing capabilities alongside BlueWhale Bio’s Synecta™ cell-derived nanoparticle platform. The partnership is set to focus on producing GMP-grade materials, potentially reducing CAR-T production time. These developments reflect Avantor’s ongoing efforts to innovate and address challenges in the bioprocessing industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.